TrialAnnals of the rheumatic diseases2022

Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial.

Andra-Rodica Balanescu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.